Weight loss / metabolic (dual GIP/GLP-1)
Tirzepatide
Mounjaro, Zepbound
FDA-approved, strong human data
Based on expert consensus from publicly available videos plus public FDA/regulatory status — not medical advice. Peptides are prescription territory; consult a physician before using anything here.
The Verdict
A dual agonist (GIP + GLP-1) that outperforms semaglutide on weight loss in trials (Attia). Same muscle-preservation rules apply — the faster the loss, the harder you defend lean mass.
The Evidence
FDA / Legal Status
FDA-approved (type 2 diabetes and obesity)
Human Evidence
Large randomized trials — more potent than semaglutide (dual GIP/GLP-1 agonist)
Sport / Doping
Prescription drug
Safety Flags
- Lean-muscle loss with rapid weight loss; protein + resistance training essential
- GI side effects during dose escalation
Who Covers It
Other experts in the panel had no substantive coverage of this peptide — we don't guess their position.
Want the deep dive on Tirzepatide?
This grade is free. Pro unlocks chat with the full expert dataset — ask about dosing, stacks, sourcing, and the exact citations behind every claim.
Cancel anytime